New drug combo aims to fight back when leukemia returns after transplant
NCT ID NCT02684162
Summary
This study tested a two-part treatment for people whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back after a donor stem cell transplant. It combined a drug called guadecitabine, which may slow cancer growth, with infusions of the donor's white blood cells to help the immune system attack remaining cancer. The goal was to see if this approach could get the cancer back under control and keep it away longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.